Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
17 déc. 2024 08h08 HE
|
Cyclerion Therapeutics, Inc.
Cyclerion is leveraging its legacy sGC stimulator assets to generate near-term revenues which will be used to implement its strategic building plan.
Regina Graul, Ph.D., Promoted to Chief Executive Officer
07 août 2024 07h00 HE
|
Cyclerion Therapeutics, Inc.
Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors of Cyclerion.
Cyclerion Appoints Regina Graul, Ph.D., as President
04 déc. 2023 08h00 HE
|
Cyclerion Therapeutics, Inc.
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht,...
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
30 nov. 2023 18h16 HE
|
Cyclerion Therapeutics, Inc.
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in...
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
31 juil. 2023 07h00 HE
|
Cyclerion Therapeutics, Inc.
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease...
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 juin 2023 16h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq...
Cyclerion Announces Reverse Stock Split
15 mai 2023 13h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse...
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
11 mai 2023 18h00 HE
|
Cyclerion Therapeutics, Inc.
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its...
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
11 mai 2023 18h00 HE
|
Cyclerion Therapeutics, Inc.
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in...
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
03 avr. 2023 07h30 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent...